Skip to content

Study of the preventive effect on frailty by low doses continuous intake of polyamine

Study of the preventive effect on frailty by low doses continuous intake of polyamine - Study of the preventive effect on frailty by low doses continuous intake of polyamine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047543
Enrollment
60
Registered
2022-04-21
Start date
2022-04-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Ingest 2 tablets of the test food (polyamine-containing capsules) each after breakfast, lunch and dinner (total 6 tablets: 1,800 mg) daily for 12 weeks. Ingest 2 tablets of the placebo food each after

Sponsors

Healthcare Systems Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Persons who received sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document 2.Japanese men who are 50 years old or more and under 65 years old

Exclusion criteria

Exclusion criteria: 1.Persons who have any chronic illnesses with medication and who have any serious disease histories 2.Persons who have any allergies to the ingredients used in the test food (especially persons who have allergies to wheat) 3.Persons who regularly take large amounts of polyamine-containing supplements 4.Persons who regularly take soy foods 5.Persons who regularly use medicines or foods with health claims (foods for specified health use, foods with functional claims and foods with nutritional claims) etc., that may affect skeletal muscle mass. 6.Persons who have participated in other tests within the past one month before the start of test, or those who intend to participate in another exam after consenting to the exam 7.Persons who were judged as inappropriate for study participant by the principal investigator

Design outcomes

Primary

MeasureTime frame
Skeletal muscle mass

Secondary

MeasureTime frame
Urine polyamine Urine deoxypyridinoline Muscle mass (Right arm, Left arm,Truncus, Right leg, Left leg) Grip strength Back muscle strength Leg strength Blood pressure (Systolic and Diastolic) Questionnaire regarding cognitive function

Countries

Japan

Contacts

Public ContactKosei Nishikawa

Healthcare Systems Co., Ltd. Clinical Research Department

nishikawa@hc-sys.jp03-6809-2722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026